drugset / Trial / NCT00240552

Fosamprenavir Expanded Access

NCT00240552

Phase 4 Completed 85 enrolled ViiV Healthcare GlaxoSmithKline · collab

Summary

This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.

Timeline

Start
2003-07
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosamprenavir Small molecule